🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,187 results for “Takeda” Clear

  1. Factor IX Concentrate (purified, virus-inactivated)

    Takeda

    Hemophilia B

    approved mab completed

    1 trial

  2. Febuxostat

    Takeda

    Gout

    approved small molecule completed

    6 trials

  3. Febuxostat

    Takeda

    Coronary Artery Disease

    approved small molecule completed

    1 trial

  4. Feiba

    Takeda

    Hemophilia A With Inhibitor

    approved small molecule active

    1 trial

  5. Ferric carboxymaltose

    Takeda

    Cardiac Failure

    approved small molecule active

    1 trial

  6. Fruquintinib

    Takeda

    Colorectal Cancer

    approved small molecule active

    1 trial

  7. Guanfacine hydrochloride (TAK-503)

    Takeda

    Attention Deficit Hyperactivity Disorder

    approved small molecule completed

    1 trial

  8. HYQVIA

    Takeda

    Primary Immunodeficiency Diseases (PID)

    approved mab completed

    2 trials

  9. Idursulfase

    Takeda

    Hunter Syndrome

    approved mab completed

    2 trials

  10. Ixazomib

    Takeda

    Relapsed and/or Refractory Multiple Myeloma

    approved small molecule terminated

    4 trials

  11. Lansoprazole

    Takeda

    Functional Dyspepsia

    approved small molecule terminated

    1 trial

  12. Lansoprazole

    Takeda

    Gastroesophageal Reflux

    approved small molecule completed

    1 trial

  13. Lansoprazole (Prevacid)

    Takeda

    Zollinger-Ellison Syndrome

    approved small molecule completed

    1 trial

  14. Lanthanum carbonate

    Takeda

    Kidney Failure, Chronic

    approved small molecule completed

    6 trials

  15. Lanthanum carbonate

    Takeda

    Kidney Diseases

    approved small molecule terminated

    2 trials

  16. Leuprorelin

    Takeda

    Central Precocious Puberty

    approved small molecule completed

    1 trial

  17. Leuprorelin Acetate Depot 3M

    Takeda

    Central Precocious Puberty

    approved small molecule completed

    1 trial

  18. Lisdexamfetamine dimesylate

    Takeda

    Attention Deficit Hyperactivity Disorder (ADHD)

    approved small molecule completed

    1 trial

  19. Lisdexamfetamine dimesylate

    Takeda

    Attention-deficit/Hyperactivity Disorder

    approved small molecule completed

    3 trials

  20. Lubiprostone

    Takeda

    Inflammatory Bowel Disease

    approved small molecule completed

    1 trial

  21. Lubiprostone

    Takeda

    Constipation

    approved small molecule completed

    7 trials

  22. Lubiprostone

    Takeda

    Multiple Sclerosis

    approved small molecule completed

    1 trial

  23. MMX Mesalamine

    Takeda

    Ulcerative Colitis

    approved small molecule completed

    2 trials

  24. MMX mesalamine/ mesalazine

    Takeda

    Ulcerative Colitis

    approved small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources